Vonoprazan poses no additional risk of developing Clostridioides difficile infection compared to proton pump inhibitors.

We found that both PPIs and vonoprazan were associated with CDI, and the magnitude of the association was comparable. Because vonoprazan is widely available in Asian countries, further studies on the association of its usage with CDI are warranted.